{"id":37400,"date":"2016-07-29T08:22:01","date_gmt":"2016-07-29T12:22:01","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=37400"},"modified":"2016-08-02T11:47:09","modified_gmt":"2016-08-02T15:47:09","slug":"anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400","title":{"rendered":"Anavex Life Sciences Corp. (NASDAQ:AVXL) Reports 31-Week Efficacy Results From ANAVEX 2-73 Phase 2a Study"},"content":{"rendered":"

Anavex Life Sciences Corp. (NASDAQ:AVXL)<\/strong> has revealed on Wednesday at the Alzheimer\u2019s Association International Conference (AAIC) 2016 a 31-week efficacy report about the ongoing ANAVEX 2-73 Phase 2a clinical trial in mild-to-moderate Alzheimer\u2019s disease.<\/p>\n

31-Week Data<\/strong><\/p>\n

So far, the efficacy report shows a consistent response for all quantitative secondary endpoints, which include cognitive and functional measures such as Alzheimer\u2019s Disease Cooperative Study\u2014 Activities of Daily Living (ADCS-ADL), Cogstate and Electroencephalographic Activity and Event-Related Potentials (EEG\/ERP), and Mini Mental State Examination (MMSE). The primary endpoint of the study is to evaluate the safety, efficacy, and tolerability, and determine the maximum tolerated dosage (MTD) of ANAVEX 2-73.<\/p>\n

According to Associate Professor Stephen Macfarlane, FRANZCP, Dementia Centre HammondCare Head of Clinical Governance, the promising results over the past 31 weeks highly indicate the ability of ANAVEX 2-73 to maintain active memory functions.<\/p>\n

Christopher Missling, Ph.D., Anavex Life Sciences CEO and President, cited the design of the Phase 2a clinical trial as adaptable for the patients without compromising their well-being. In line with this, Missling noted that the company is already planning for a Phase \u2154 clinical trial.<\/p>\n

ANAVEX 2-73<\/strong><\/p>\n

Last month, ANAVEX 2-73 has received from the US Food and Drug Administration (FDA) an Orphan Drug Designation for the treatments of infantile spasms. This follows the granting of the Orphan Drug Designation last May to ANAVEX 2-73 for the treatment of Rett syndrome.<\/p>\n

Such designation is granted to treatments that have potential therapeutic benefits for safely curing rare diseases, which affect less than 200,000 individuals in the US. Treatments with Orphan Drug Designations are entitled to prioritized consultations with the US FDA and numerous development program and commercialization incentives.<\/p>\n

In June, Anavex Life Sciences has also issued encouraging data of ANAVEX 2-73 from an exploratory study for the treatment of Fragile X syndrome. With a Fragile X syndrome rat model, the company noted that ANAVEX 2-73 has potential therapeutic benefits for those who are suffering from Fragile X syndrome and Autism Spectrum Disorders as well.<\/p>\n","protected":false},"excerpt":{"rendered":"

Anavex Life Sciences Corp. (NASDAQ:AVXL) has revealed on Wednesday at the Alzheimer\u2019s Association International Conference (AAIC) 2016 a 31-week efficacy report about the ongoing ANAVEX […]<\/p>\n","protected":false},"author":13,"featured_media":37475,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[11990,11989,11992,11991,11993],"stock_ticker":[],"class_list":["post-37400","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-anavex-life-sciences-corp","tag-anavex-life-sciences-corp-nasdaqavxl","tag-christopher-missling","tag-nasdaqavxl","tag-stephen-macfarlane","entry"],"acf":[],"yoast_head":"\nAnavex Life Sciences Corp. (NASDAQ:AVXL) Reports 31-Week Efficacy Results From ANAVEX 2-73 Phase 2a Study - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anavex Life Sciences Corp. (NASDAQ:AVXL) Reports 31-Week Efficacy Results From ANAVEX 2-73 Phase 2a Study - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Anavex Life Sciences Corp. (NASDAQ:AVXL) has revealed on Wednesday at the Alzheimer\u2019s Association International Conference (AAIC) 2016 a 31-week efficacy report about the ongoing ANAVEX […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-07-29T12:22:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2016-08-02T15:47:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/07\/et-wealth-want-to-ride-the-market-rally-know-which-stocks-you-should-buy.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"450\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lisa Ray\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lisa Ray\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400\"},\"author\":{\"name\":\"Lisa Ray\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/c58aa72f5e3994c817e3654937496b1c\"},\"headline\":\"Anavex Life Sciences Corp. (NASDAQ:AVXL) Reports 31-Week Efficacy Results From ANAVEX 2-73 Phase 2a Study\",\"datePublished\":\"2016-07-29T12:22:01+00:00\",\"dateModified\":\"2016-08-02T15:47:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400\"},\"wordCount\":350,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/07\/et-wealth-want-to-ride-the-market-rally-know-which-stocks-you-should-buy.jpg\",\"keywords\":[\"Anavex Life Sciences Corp.\",\"Anavex Life Sciences Corp. (NASDAQ:AVXL)\",\"Christopher Missling\",\"NASDAQ:AVXL\",\"Stephen Macfarlane\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400\",\"name\":\"Anavex Life Sciences Corp. (NASDAQ:AVXL) Reports 31-Week Efficacy Results From ANAVEX 2-73 Phase 2a Study - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/07\/et-wealth-want-to-ride-the-market-rally-know-which-stocks-you-should-buy.jpg\",\"datePublished\":\"2016-07-29T12:22:01+00:00\",\"dateModified\":\"2016-08-02T15:47:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/07\/et-wealth-want-to-ride-the-market-rally-know-which-stocks-you-should-buy.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/07\/et-wealth-want-to-ride-the-market-rally-know-which-stocks-you-should-buy.jpg\",\"width\":600,\"height\":450},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anavex Life Sciences Corp. (NASDAQ:AVXL) Reports 31-Week Efficacy Results From ANAVEX 2-73 Phase 2a Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/c58aa72f5e3994c817e3654937496b1c\",\"name\":\"Lisa Ray\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/2b2b9819092dcc9a125cbbf7b3645b09.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/2b2b9819092dcc9a125cbbf7b3645b09.png\",\"caption\":\"Lisa Ray\"},\"description\":\"Lisa has a Bachelor of Arts in journalism from Purdue University and 3 years of experience in the publishing field.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/linsay-thomas\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anavex Life Sciences Corp. (NASDAQ:AVXL) Reports 31-Week Efficacy Results From ANAVEX 2-73 Phase 2a Study - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400","og_locale":"en_US","og_type":"article","og_title":"Anavex Life Sciences Corp. (NASDAQ:AVXL) Reports 31-Week Efficacy Results From ANAVEX 2-73 Phase 2a Study - Wall Street PR","og_description":"Anavex Life Sciences Corp. (NASDAQ:AVXL) has revealed on Wednesday at the Alzheimer\u2019s Association International Conference (AAIC) 2016 a 31-week efficacy report about the ongoing ANAVEX […]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2016-07-29T12:22:01+00:00","article_modified_time":"2016-08-02T15:47:09+00:00","og_image":[{"width":600,"height":450,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/07\/et-wealth-want-to-ride-the-market-rally-know-which-stocks-you-should-buy.jpg","type":"image\/jpeg"}],"author":"Lisa Ray","twitter_misc":{"Written by":"Lisa Ray","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400"},"author":{"name":"Lisa Ray","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/c58aa72f5e3994c817e3654937496b1c"},"headline":"Anavex Life Sciences Corp. (NASDAQ:AVXL) Reports 31-Week Efficacy Results From ANAVEX 2-73 Phase 2a Study","datePublished":"2016-07-29T12:22:01+00:00","dateModified":"2016-08-02T15:47:09+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400"},"wordCount":350,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/07\/et-wealth-want-to-ride-the-market-rally-know-which-stocks-you-should-buy.jpg","keywords":["Anavex Life Sciences Corp.","Anavex Life Sciences Corp. (NASDAQ:AVXL)","Christopher Missling","NASDAQ:AVXL","Stephen Macfarlane"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400","url":"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400","name":"Anavex Life Sciences Corp. (NASDAQ:AVXL) Reports 31-Week Efficacy Results From ANAVEX 2-73 Phase 2a Study - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/07\/et-wealth-want-to-ride-the-market-rally-know-which-stocks-you-should-buy.jpg","datePublished":"2016-07-29T12:22:01+00:00","dateModified":"2016-08-02T15:47:09+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/07\/et-wealth-want-to-ride-the-market-rally-know-which-stocks-you-should-buy.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2016\/07\/et-wealth-want-to-ride-the-market-rally-know-which-stocks-you-should-buy.jpg","width":600,"height":450},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/anavex-life-sciences-corp-nasdaqavxl-reports-31-week-efficacy-results-from-anavex-2-73-phase-2a-study-37400#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Anavex Life Sciences Corp. (NASDAQ:AVXL) Reports 31-Week Efficacy Results From ANAVEX 2-73 Phase 2a Study"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/c58aa72f5e3994c817e3654937496b1c","name":"Lisa Ray","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/2b2b9819092dcc9a125cbbf7b3645b09.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/2b2b9819092dcc9a125cbbf7b3645b09.png","caption":"Lisa Ray"},"description":"Lisa has a Bachelor of Arts in journalism from Purdue University and 3 years of experience in the publishing field.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/linsay-thomas"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/37400","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=37400"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/37400\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/37475"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=37400"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=37400"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=37400"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=37400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}